Prospects for the listing of Sotoracib (AMG510) in China

Sotoracib (AMG510), this highly anticipated targeted drug, is specifically targeted at patients with advanced non-small cell lung cancer (NSCLC) with positive KRAS gene mutations. KRAS mutation is one of the difficult treatment problems in NSCLC, and the advent of sotorasib undoubtedly brings new hope to the field of lung cancer treatment.

Sotorasiib precisely inhibits the active protein of KRAS G12C mutant, effectively blocking abnormal cell signaling, thereby curbing the growth and spread of tumor cells. In clinical trials, sotoracib has shown encouraging therapeutic effects. Some patients' tumors have significantly shrunk or even achieved complete remission, and their survival has been significantly prolonged.

Amgen's CodeBreaK 100 trial further verified the efficacy of sotoraxib. In this trial, a group of patients with solid tumors suffering from KRAS G12C mutations were included, most of whom were patients with non-small cell lung cancer, and most of the patients had previously received immunotherapy and/or chemotherapy. The results of the study showed that 4 of the patients who received sotorasibu had their tumors completely disappear, 42 had their tumors partially shrink, and the condition of 54 others remained stable. This result undoubtedly lays a solid foundation for sotoraxib's future clinical application.

However, although sotoracib has been approved byFDA and successfully launched in the United States, it still faces many challenges in the Chinese market. As of March 2024, sotorasibu has not yet obtained marketing approval in China. Drugs need to go through a series of strict approval processes before they are marketed in China, including clinical trials, registration applications, review and approval, etc. They also need to meet the relevant requirements of the State Food and Drug Administration. These processes are not only time-consuming, but also involve certain uncertainties.